Escherichia coli strain Nissle 1917 (EcN) is a remarkable probiotic bacterium, first described by Alfred Nissle in 1916/17. As the active component of Mutaflor, EcN has been well researched over decades but detailed mechanisms by which EcN confers its probiotic effects are still elusive. EcN however, has a unique profile concerning fitness Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor(®) (Ardeypharm GmbH, Herdecke, Germany and EcN, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. At entry, all patients were randomised by an independent pharmacy in a double-blind, double-dummy fashion to receive either mesalazine (Asacol formulation) 800 mg three times daily or a non-pathogenic strain of E coli (serotype O6:K5:H1) named Nissle 1917 (Mutaflor, Ardeypharm GmbH, Herdecke, Germany) at a dose of two capsules twice daily (2·5 In a recent article published in Nature, Roger Geiger's research group showed that the engineered bacterial strain Escherichia coli Nissle 1917 (ECN) could recycle ammonia into L-arginine (Arg Mutaflor® is a probiotic composed of Escherichia coli of the strain Nissle 1917. It is manufactured in Germany and available in Canada and several countries in Europe and Asia.. It is available in Australia without prescription from selected pharmacies and medical dispensaries. New Zealand Pharmacies can supply Mutaflor® to a patient on request from an authorized prescriber based on Section E coli Nissle 1917 has demonstrated an ability to exert beneficial effects on various gastrointestinal disorders and is one of the most extensively studied probiotic strains of bacteria. It was first isolated in 1917 from the faeces of a soldier during the First World War, by a Professor Alfred Nissle. Mutaflor ® is commonly used in the .

mutaflor e coli nissle 1917